Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free PSNL Stock Alerts

Personalis (PSNL) Competitors

Personalis logo
$5.56 -0.34 (-5.76%)
Closing price 04:00 PM Eastern
Extended Trading
$5.56 +0.00 (+0.04%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PSNL vs. DFTX, GRAL, WGS, SGRY, and ADUS

Should you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Definium Therapeutics (DFTX), GRAIL (GRAL), GeneDx (WGS), Surgery Partners (SGRY), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry.

How does Personalis compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 2.3% of Definium Therapeutics shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Definium Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.

Definium Therapeutics has a net margin of 0.00% compared to Personalis' net margin of -116.69%. Personalis' return on equity of -39.13% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -82.07% -58.73%
Personalis -116.69%-39.13%-29.31%

Personalis has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$2.13N/A
Personalis$69.65M8.36-$81.27M-$0.91N/A

In the previous week, Definium Therapeutics and Definium Therapeutics both had 5 articles in the media. Definium Therapeutics' average media sentiment score of 1.02 beat Personalis' score of 0.73 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Personalis
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Definium Therapeutics currently has a consensus target price of $38.00, indicating a potential upside of 69.64%. Personalis has a consensus target price of $11.50, indicating a potential upside of 106.83%. Given Personalis' higher possible upside, analysts plainly believe Personalis is more favorable than Definium Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
3 Strong Buy rating(s)
3.07
Personalis
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Personalis beats Definium Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Personalis compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Personalis has a net margin of -116.69% compared to GRAIL's net margin of -277.46%. GRAIL's return on equity of -17.11% beat Personalis' return on equity.

Company Net Margins Return on Equity Return on Assets
GRAIL-277.46% -17.11% -14.75%
Personalis -116.69%-39.13%-29.31%

GRAIL presently has a consensus price target of $68.63, indicating a potential upside of 26.15%. Personalis has a consensus price target of $11.50, indicating a potential upside of 106.83%. Given Personalis' stronger consensus rating and higher possible upside, analysts clearly believe Personalis is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRAIL
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Personalis
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, GRAIL had 1 more articles in the media than Personalis. MarketBeat recorded 6 mentions for GRAIL and 5 mentions for Personalis. Personalis' average media sentiment score of 0.73 beat GRAIL's score of 0.16 indicating that Personalis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRAIL
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Personalis
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Personalis has lower revenue, but higher earnings than GRAIL. Personalis is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRAIL$147.17M15.86-$408.35M-$11.18N/A
Personalis$69.65M8.36-$81.27M-$0.91N/A

GRAIL has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Personalis beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does Personalis compare to GeneDx?

GeneDx (NASDAQ:WGS) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

GeneDx has a net margin of -4.92% compared to Personalis' net margin of -116.69%. GeneDx's return on equity of 14.73% beat Personalis' return on equity.

Company Net Margins Return on Equity Return on Assets
GeneDx-4.92% 14.73% 8.67%
Personalis -116.69%-39.13%-29.31%

GeneDx currently has a consensus target price of $96.43, suggesting a potential upside of 179.42%. Personalis has a consensus target price of $11.50, suggesting a potential upside of 106.83%. Given GeneDx's stronger consensus rating and higher possible upside, research analysts plainly believe GeneDx is more favorable than Personalis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeneDx
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Personalis
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, GeneDx had 28 more articles in the media than Personalis. MarketBeat recorded 33 mentions for GeneDx and 5 mentions for Personalis. Personalis' average media sentiment score of 0.73 beat GeneDx's score of 0.19 indicating that Personalis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GeneDx
6 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
6 Negative mention(s)
2 Very Negative mention(s)
Neutral
Personalis
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GeneDx has higher revenue and earnings than Personalis. GeneDx is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneDx$427.54M2.36-$21.02M-$0.75N/A
Personalis$69.65M8.36-$81.27M-$0.91N/A

GeneDx has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.

61.7% of GeneDx shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 29.6% of GeneDx shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

GeneDx beats Personalis on 12 of the 16 factors compared between the two stocks.

How does Personalis compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Surgery Partners has higher revenue and earnings than Personalis. Surgery Partners is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgery Partners$3.31B0.56-$77.90M-$0.62N/A
Personalis$69.65M8.36-$81.27M-$0.91N/A

Surgery Partners currently has a consensus target price of $22.00, suggesting a potential upside of 54.28%. Personalis has a consensus target price of $11.50, suggesting a potential upside of 106.83%. Given Personalis' stronger consensus rating and higher probable upside, analysts clearly believe Personalis is more favorable than Surgery Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surgery Partners
2 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50
Personalis
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Surgery Partners has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.

61.9% of Personalis shares are owned by institutional investors. 2.7% of Surgery Partners shares are owned by company insiders. Comparatively, 4.2% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Surgery Partners has a net margin of -2.35% compared to Personalis' net margin of -116.69%. Surgery Partners' return on equity of 1.28% beat Personalis' return on equity.

Company Net Margins Return on Equity Return on Assets
Surgery Partners-2.35% 1.28% 0.51%
Personalis -116.69%-39.13%-29.31%

In the previous week, Surgery Partners had 6 more articles in the media than Personalis. MarketBeat recorded 11 mentions for Surgery Partners and 5 mentions for Personalis. Surgery Partners' average media sentiment score of 0.91 beat Personalis' score of 0.73 indicating that Surgery Partners is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Surgery Partners
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Personalis
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Surgery Partners beats Personalis on 10 of the 16 factors compared between the two stocks.

How does Personalis compare to Addus HomeCare?

Personalis (NASDAQ:PSNL) and Addus HomeCare (NASDAQ:ADUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

61.9% of Personalis shares are owned by institutional investors. Comparatively, 95.3% of Addus HomeCare shares are owned by institutional investors. 4.2% of Personalis shares are owned by company insiders. Comparatively, 4.5% of Addus HomeCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Personalis currently has a consensus target price of $11.50, suggesting a potential upside of 106.83%. Addus HomeCare has a consensus target price of $133.22, suggesting a potential upside of 35.33%. Given Personalis' higher possible upside, equities research analysts clearly believe Personalis is more favorable than Addus HomeCare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Personalis
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Addus HomeCare
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.73

Addus HomeCare has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Personalis$69.65M8.36-$81.27M-$0.91N/A
Addus HomeCare$1.42B1.29$95.91M$5.2118.89

Addus HomeCare has a net margin of 6.74% compared to Personalis' net margin of -116.69%. Addus HomeCare's return on equity of 9.84% beat Personalis' return on equity.

Company Net Margins Return on Equity Return on Assets
Personalis-116.69% -39.13% -29.31%
Addus HomeCare 6.74%9.84%7.19%

In the previous week, Addus HomeCare had 4 more articles in the media than Personalis. MarketBeat recorded 9 mentions for Addus HomeCare and 5 mentions for Personalis. Addus HomeCare's average media sentiment score of 1.04 beat Personalis' score of 0.73 indicating that Addus HomeCare is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Personalis
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Addus HomeCare
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Personalis has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Addus HomeCare has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

Summary

Addus HomeCare beats Personalis on 14 of the 17 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PSNL vs. The Competition

Export
MetricPersonalisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$582.01M$6.05B$6.25B$11.87B
Dividend YieldN/A0.72%2.73%5.21%
P/E Ratio-6.117.9629.0428.48
Price / Sales8.3624.44476.4860.89
Price / CashN/A8.2527.6236.52
Price / Book1.894.279.676.67
Net Income-$81.27M$118.49M$3.55B$332.64M
7 Day Performance1.09%3.14%1.70%2.01%
1 Month Performance-15.50%6.63%5.62%9.19%
1 Year Performance30.52%197.09%34.42%39.59%

Personalis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PSNL
Personalis
2.6032 of 5 stars		$5.56
-5.8%		$11.50
+106.8%		N/A$582.01M$69.65MN/A400
DFTX
Definium Therapeutics
3.8526 of 5 stars		$20.98
-6.7%		$38.00
+81.1%		N/A$2.24BN/AN/A40
GRAL
GRAIL
3.0461 of 5 stars		$55.02
+1.1%		$68.63
+24.7%		N/A$2.23B$147.17MN/A1,360
WGS
GeneDx
4.1593 of 5 stars		$66.17
-3.4%		$130.71
+97.5%		N/A$2.01B$427.54MN/A1,300
SGRY
Surgery Partners
3.745 of 5 stars		$14.54
+1.4%		$22.00
+51.3%		N/A$1.88B$3.31BN/A16,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel